bullish

Telix Pharmaceuticals - A look at future directions

101 Views08 Sep 2020 20:54
Issuer-paid
SUMMARY

For the first time, Telix provided a profile of its deep pipeline outside its lead asset on its H120 earnings call. It presented the details of four assets derived from its existing pipeline, the majority of which are expected to be tested in the clinic before the end of the year. This provides a roadmap for the company beyond the upcoming potential approval for TLX591-CDx and completion of pivotal studies for TLX250-CDx.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Edison Investment Research
Leading International Investment Research
Equities
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x